Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). According to GlobalData, Phase I drugs for Genital Warts (Condylomata Acuminata) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase I drugs for Cervical Intraepithelial Neoplasia (CIN) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Drug Discovery World

NOVEMBER 30, 2023

The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation for FT011 for the treatment of systemic sclerosis (scleroderma). It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

Drug Trials 59

Drug Trials Trials Drugs Clinical Trials 59

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

pharmaphorum

MAY 14, 2021

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. Lu declined to comment further on its announcement that the first patient had been dosed with the drug in the US trial.

Drug Trials 52

Drug Trials Trials Drugs Dermatology 52

Drug Discovery World

MARCH 13, 2024

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor.

Trials 52

Trials Dermatology Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 18, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

pharmaphorum

OCTOBER 5, 2022

The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that is mutated in FSHD – with a nanobody developed by Sanofi that targets muscle cells. .” billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

XTalks

MAY 19, 2023

Types of Registered Studies According to ClinicalTrials.gov, as of May 2023, 77 percent of registered studies are interventional, with a significant portion of these focusing on drugs or biologics (181,721 studies or around 40 percent of all trials) and a smaller portion on devices (46,809 studies or around 10 percent of all trials).

Clinical Trials 97

Clinical Trials Clinical Trials Trials Clinical Research 97

The Pharma Data

MARCH 28, 2022

The focus of the event is on Dupixent ® (dupilumab), a key growth driver, and Sanofi’s rapidly advancing pipeline, highlighting dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

Medicine 52

Medicine Sales Clinical Development Development 52

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

Delveinsight

AUGUST 25, 2021

The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, or relieve symptoms. Pharmaceutical companies may deal in both generic and brand-name drugs as well as medical devices.

Vaccination 98

Vaccination Vaccine Sales Drugs 98

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

AUGUST 1, 2021

The approval by the Food and Drug Administration (FDA) was based on efficacy and safety data from the Saphnelo clinical development programme, including two TULIP Phase III trials and the MUSE Phase II trial. 7,8,9,10,11.

Trials 52

Trials Clinical Development Antibody Dermatology 52

The Pharma Data

JUNE 7, 2022

Food and Drug Administration (FDA) for lebrikizumab in AD in the second half of 2022, followed by submissions to other regulatory agencies around the world. These studies are part of the comprehensive clinical development program for lebrikizumab in AD evaluating more than 2,000 patients. About Lebrikizumab.

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 4, 2020

Food and Drug Administration (FDA) Breakthrough Therapy and Fast Track Designations, is now in pivotal testing, and CTP-692 for schizophrenia is currently on track for topline data readout in the first quarter of 2021,” said Roger Tung, Ph.D., CTP-543 for moderate to severe alopecia areata, which received U.S. .

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

The Pharma Data

AUGUST 19, 2021

Food and Drug Administration (FDA) approval for patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, based on data showing an ORR of 40 percent (95 percent CI, 29 – 51) and median duration of response of 11.1 Dermatologic Adverse Reactions 7. of patients.

FDA Approval 52

FDA Approval Dermatology Genetics Development 52

The Pharma Data

NOVEMBER 8, 2020

Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. “Our solid results confirm that we are on the right track to strengthen our leadership position in the medical dermatology space. .

Dermatology 52

Dermatology Sales Marketing Production 52

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 13, 2021

14, 2021 (GLOBE NEWSWIRE) — Innovation Pharma (Formerly known as Cellceutix) (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the U.S. WAKEFIELD, Mass., Brilacidin is a first-in-class Host Defense Protein (HDP) mimetic with antiviral, anti-inflammatory and antibacterial properties.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

Pharma Marketing Network

APRIL 30, 2021

Across the board, from rheumatology to neurology, outcomes that matter most to patients, have traditionally not been captured in clinical trials. In recent years, an increasingly-discussed goal has been improving the diversity of clinical trial enrollment so that study populations better reflect the likely end-users of the drug.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Regulation 52

The Pharma Data

MARCH 4, 2021

Food and Drug Administration (FDA) for the treatment of AA. associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. vice president of immunology development at Lilly. WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS.

Trials 52

Trials Development Dermatology Clinical Trials 52

The Pharma Data

APRIL 4, 2023

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. This marks the first time an anti-PD-1 therapy has been approved in combination with anantibody-drug conjugate in the U.S.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

JULY 23, 2021

Food and Drug Administration (FDA), Bristol Myers Squibb has made the difficult decision to voluntarily withdraw the indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who were previously treated with sorafenib from the U.S. endocrinopathies and dermatologic reactions) are discussed below.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

Food and Drug Administration (FDA) will hold a public meeting of the Oncologic Drugs Advisory Committee (ODAC) between April 27-29, 2021 to discuss accelerated approvals in oncology impacted as part of the Agency’s industry-wide review. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Genome Genomics 52

Pfizer

OCTOBER 28, 2022

XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in rheumatoid arthritis (RA) patients, and prescribed to more than 362,000 adult patients (the majority of whom were RA patients) worldwide since 2012. patients with a history of diverticulitis or taking NSAIDs). HYPERSENSITIVITY.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. KENILWORTH, N.J.–(BUSINESS

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

SEPTEMBER 15, 2020

In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. 20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

AUGUST 11, 2020

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52